Renal denervation in truly resistant hypertensive patients: six-year follow-up results of a single-center study

Abstract Background Renal sympathetic denervation (RDN) is one of the invasive treatment options for the patients with hypertension (HTN) who are resistant to antihypertensive therapy (AHT). The short-term efficacy of RDN has been proven in a number of randomized clinical trials, but remains controv...

Full description

Saved in:
Bibliographic Details
Published in:European heart journal 2021-10, Vol.42 (Supplement_1)
Main Authors: Ionov, M, Emelyanov, I V, Yudina, Y S, Panarina, S A, Zverev, D A, Avdonina, N G, Zvartau, N E, Konradi, A O
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Renal sympathetic denervation (RDN) is one of the invasive treatment options for the patients with hypertension (HTN) who are resistant to antihypertensive therapy (AHT). The short-term efficacy of RDN has been proven in a number of randomized clinical trials, but remains controversial, the data on its long-term efficacy are limited. Purpose To evaluate the natural course of HTN, to assess long-term major adverse cardiovascular events (MACEs) and other clinically significant outcomes, as well as AHT efficacy and its features in patients with truly resistant HTN after bilateral RDN during extended prospective follow-up. Methods We included 22 patients with truly resistant HTN (median 57 y.o., 9 males), in whom RDN was performed during 2012–2015 in the clinical center of excellence. We assessed initial and further (after 1 year and after ≥5 years) office and 24-hour BP values, as well as AHT history in detail. Long-term MACEs and other cancer-related outcomes were recorded. The baseline quality of life (QoL) and its dynamics were assessed with the use of EQ-5D-5L questionnaire at all timepoints. Multiple linear regression was used to find possible predictors of the efficacy of RDN. Results The median follow-up after the RDN was 6 (from 5 to 8) years. A significant decrease in office and 24-hour systolic (S) and diastolic BPs was observed at 12 months after RDN compared to initial values (Δ −24 and −12 mm Hg, p
ISSN:0195-668X
1522-9645
DOI:10.1093/eurheartj/ehab724.2371